Iradimed (IRMD) & CELLECT BIOTECH/S (APOP) Head-To-Head Contrast

Iradimed (NASDAQ: APOP) and CELLECT BIOTECH/S (NASDAQ:APOP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Risk & Volatility

Iradimed has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, CELLECT BIOTECH/S has a beta of 3.6, meaning that its stock price is 260% more volatile than the S&P 500.

Institutional and Insider Ownership

19.9% of Iradimed shares are held by institutional investors. Comparatively, 3.7% of CELLECT BIOTECH/S shares are held by institutional investors. 61.2% of Iradimed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Iradimed and CELLECT BIOTECH/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iradimed 9.57% 8.99% 7.61%
CELLECT BIOTECH/S N/A -93.06% -60.94%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Iradimed and CELLECT BIOTECH/S, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iradimed 0 0 2 0 3.00
CELLECT BIOTECH/S 0 0 1 0 3.00

Iradimed presently has a consensus target price of $22.50, indicating a potential downside of 20.35%. CELLECT BIOTECH/S has a consensus target price of $14.00, indicating a potential upside of 187.47%. Given CELLECT BIOTECH/S’s higher probable upside, analysts plainly believe CELLECT BIOTECH/S is more favorable than Iradimed.

Valuation and Earnings

This table compares Iradimed and CELLECT BIOTECH/S’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Iradimed $23.08 million 13.07 $490,000.00 $0.08 353.13
CELLECT BIOTECH/S N/A N/A -$8.14 million ($1.46) -3.34

Iradimed has higher revenue and earnings than CELLECT BIOTECH/S. CELLECT BIOTECH/S is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.


Iradimed beats CELLECT BIOTECH/S on 10 of the 12 factors compared between the two stocks.

Iradimed Company Profile

IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.


Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with's FREE daily email newsletter.

Leave a Reply